The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies
Open accessAbstract
Atypical hemolytic uremic syndrome (aHUS) is a rare, possibly life-threatening disease characterized by platelet activation, hemolysis and thrombotic microangiopathy (TMA) leading to renal and other end-organ damage. We originally conducted two phase 2 studies (26 weeks and 1 year) evaluating eculizumab, a terminal complement inhibitor, in patients with progressing TMA (trial 1) and those with long duration of aHUS and chronic kidney disease (trial 2). The current analysis assessed outcomes after 2 years (median eculizumab exposure 100 and 114 weeks, respectively). At all scheduled time points, eculizumab inhibited terminal complement activity. In trial 1 with 17 patients, the platelet count was significantly improved from baseline, and hematologic normalization was achieved in 13 patients at week 26, and in 15 patients at both 1 and 2 years. The estimated glomerular filtration rate (eGFR) was significantly improved compared with baseline and year 1. In trial 2 with 20 patients, TMA event-free status was achieved by 16 patients at week 26, 17 patients at year 1, and 19 patients at year 2. Criteria for hematologic normalization were met by 18 patients at each time point. Improvement of 15 ml/min per 1.73 m(2) or more in eGFR was achieved by 1 patient at week 26, 3 patients at 1 year, and 8 patients at 2 years. The mean change in eGFR was not significant compared with baseline, week 26, or year 1. Eculizumab was well tolerated, with no new safety concerns or meningococcal infections. Thus, a 2-year analysis found that the earlier clinical benefits achieved by eculizumab treatment of aHUS were maintained at 2 years of follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Levey, A. S., Coresh, J., Greene, T., Marsh, J., Stevens, L. A., Kusek, J. W., Van Lente, F., & for Chronic Kidney Disease Epidemiology Collaboration (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.077180 · Cited by 1,855
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Self-citationAtypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationSyndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Self-citationEstimation of minimally important differences in EQ-5D utility and VAS scores in cancer
Pickard, A. S., Neary, M. P., & Cella, D. (2007) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-5-70 · Cited by 929
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Fremeaux-Bacchi, V., Fakhouri, F., Garnier, A., Bienaimé, F., Dragon-Durey, M.-A., Ngo, S., Moulin, B., Servais, A., Provot, F., Rostaing, L., et al. (2013) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04760512 · Cited by 714
Self-citationFRETS‐VWF73, a first fluorogenic substrate for ADAMTS13 assay
Kokame, K., Nobe, Y., Kokubo, Y., Okayama, A., & Miyata, T. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05420.x · Cited by 606
Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810739 · Cited by 554
Self-citationUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Self-citationRecessive mutations in DGKE cause atypical hemolytic-uremic syndrome
Lemaire, M., Frémeaux-Bacchi, V., Schaefer, F., Choi, M., Tang, W. H., Le Quintrec, M., Fakhouri, F., Taque, S., Nobili, F., Martinez, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2590 · Cited by 483
Self-citationGuideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
The European Paediatric Study Group for HUS, Ariceta, G., Besbas, N., Johnson, S., Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C. M., et al. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-0964-1 · Cited by 352
Self-citationCampistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., et al. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.005 · Cited by 272
Le Quintrec, M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12077 · Cited by 268
Self-citationBu, F., Maga, T., Meyer, N. C., Wang, K., Thomas, C. P., Nester, C. M., & Smith, R. J. H. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050453 · Cited by 242
Rinder, C. S., Rinder, H. M., Smith, B. R., Fitch, J. C., Smith, M. J., Tracey, J. B., Matis, L. A., Squinto, S. P., & Rollins, S. A. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118195 · Cited by 213
Ardissino, G., Testa, S., Possenti, I., Tel, F., Paglialonga, F., Salardi, S., Tedeschi, S., Belingheri, M., & Cugno, M. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.434 · Cited by 201
Quality of Life in Patients Undergoing Hemodialysis or Peritoneal Dialysis Treatment
Theofilou (2011) · Journal of Clinical Medicine Research · doi:10.4021/jocmr552w · Cited by 163
Remuzzi, A., Gagliardini, E., Sangalli, F., et al. (2006) · Kidney International · doi:10.1038/sj.ki.5000060 · Cited by 118
Peritubular capillary rarefaction: a new therapeutic target in chronic kidney disease
Kida, Y., Tchao, B. N., & Yamaguchi, I. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2430-y · Cited by 117
Plasmatherapy in Atypical Hemolytic Uremic Syndrome
Loirat, C., Garnier, A., Leclerc, A.-L. S., et al. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1262890 · Cited by 102
Self-citationPodocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace Inhibition
Macconi, D., Sangalli, F., Bonomelli, M., Conti, S., Condorelli, L., Gagliardini, E., Remuzzi, G., & Remuzzi, A. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080227 · Cited by 101
Self-citationAn update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyo, J. M., Macia, M. L., Mendizábal, S., Praga, M., et al. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.11.006 · Cited by 100
Platelet-associated complement factor H in healthy persons and patients with atypical HUS
Licht, C. P. B., Pluthero, F. G., Li, L., Christensen, H., Habbig, S., Höppe, B., Geary, D. F., Zipfel, P. F., & Kahr, W. H. A. (2009) · Blood · doi:10.1182/blood-2009-03-205096 · Cited by 82
Self-citationGülleroğlu, K., Fidan, K., Hançer, V. S., Bayrakçı, U. S., Baskın, E., & Söylemezoğlu, O. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2416-9 · Cited by 75
Eculizumab: A Review of Its Use in Atypical Haemolytic Uraemic Syndrome
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0147-7 · Cited by 65
The use of eculizumab in renal transplantation
Barnett, N., Asgari, E., Chowdhury, P., Sacks, S. H., Dorling, A., & Mamode, N. (2013) · Clinical Transplantation · doi:10.1111/ctr.12102 · Cited by 59
Thrombotic microangiopathies: new insights and new challenges
Zipfel, P. F., Heinen, S., & Skerka, C. (2010) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32833aff4a · Cited by 52
Eculizumab therapy in a child with hemolytic uremic syndrome and CFI mutation
Çaycı, F. Ş., Çakar, N., Hançer, V. S., Uncu, N., Acar, B. Ç., & Gür, G. (2012) · Pediatric Nephrology · doi:10.1007/s00467-012-2283-9 · Cited by 39
Carr, R. M., & Cataland, S. R. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1622-z · Cited by 38
Alachkar, N., Bagnasco, S. M., & Montgomery, R. A. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01497.x · Cited by 37
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
Self-citationGoodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., Nester, C. M., Noris, M., Pickering, M. C., Rodríguez de Córdoba, S., et al. (2017) · Kidney International · doi:10.1016/j.kint.2016.10.005 · Cited by 701
Self-citationAtypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Self-citationInternational, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Self-citation
Metadata
- Authors
- Licht, C., Greenbaum, L. A., Muus, P., Babu, S., Bedrosian, C. L., Cohen, D. J., Delmas, Y., Douglas, K., Furman, R. R., Gaber, O. A., Goodship, T., Herthelius, M., Hourmant, M., Legendre, C. M., Remuzzi, G., Sheerin, N., Trivelli, A., & Loirat, C.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 87
- Issue
- 5
- Pages
- 1061-1073
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2017235356
- Cited by
- 420
- References
- 36
- FWCI
- 21.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.